Histopathologic grading of oral mucositis
G Sunavala-Dossabhoy1, F Abreo, P S Timiri Shanmugam
1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, and Feist-Weiller Cancer Center, Shreveport, LA, USA.
Oral Diseases
|August 30, 2014
Summary
A new histopathologic scoring system for oral mucositis aims to standardize severity grading in animal models. This objective grading is crucial for comparing novel therapeutics and improving cancer treatment consistency.
Area of Science:
- Radiation oncology
- Cancer therapeutics research
- Preclinical animal models
Background:
- Oral mucositis (OM) is a severe side effect of chemotherapy and radiation therapy.
- Current subjective grading systems hinder consistent evaluation of OM severity and therapeutic efficacy.
- Standardized, objective grading is essential for advancing OM treatment research.
Purpose of the Study:
- To develop and propose a standardized histopathologic scoring system for oral mucositis.
- To enable objective and reproducible grading of OM severity in preclinical studies.
- To facilitate reliable comparison and validation of novel OM therapeutics.
Main Methods:
- Male Balb/C animals were subjected to fractionated radiation (3x8 Gy) or single-dose radiation (22.5 Gy) to the head.
- Histologic analysis of tongue tissue was performed at various time points post-irradiation.
- Evaluation focused on epithelial changes, including atypia, atrophy, dyskeratosis, and ulceration.
Main Results:
- Fractionated radiation induced early epithelial atypia by day 6, progressing to atrophy and ulceration by day 9.
- Single-dose radiation resulted in bulla formation by day 9 in most animals.
- Distinct histopathologic changes were observed between the two radiation fractionation schemes.
Conclusions:
- A histopathologic scoring system for oral mucositis based on tissue analysis is proposed.
- This system offers an objective method for grading OM severity in animal models.
- Implementation of this system can enhance the reliability of preclinical therapeutic evaluations.
